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Background: In the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic
radiotherapy (RT) with or without concurrent and adjuvant chemotherapy (two cycles of cisplatin 50mg/m2 in weeks 1 and 4 of
RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175mg/m2). Pathology review was required before patient
enrolment. The aim of this analysis was to evaluate the role of central pathology review before randomisation.
Patients and methods: A total of 1295 cases underwent pathology review to confirm HR-EC in the Netherlands (n¼ 395) and
the UK (n¼ 900), and for 1226/1295 (95%) matching review and original reports were available. In total, 329 of these patients
were enrolled in the PORTEC-3 trial: 145 in the Netherlands and 184 in the UK, comprising 48% of the total PORTEC-3 cohort of
686 participants. Areas of discrepancies were evaluated, and inter-observer agreement between original and review opinion
was evaluated by calculating the kappa value (j).
Results: In the 1226 pathology reviews, 6356 selected items were evaluable for both original and review pathology. In 43% of
cases at least one pathology item changed after review. For 102 patients (8%), this discrepancy led to ineligibility for the
PORTEC-3 trial, most frequently due to differences in the assessment of histological type (34%), endocervical stromal
involvement (27%) and histological grade (19%). Lowest inter-observer agreement was found for histological type (j¼ 0.72),
lymph-vascular space invasion (j¼ 0.72) and histological grade (j¼ 0.70).
Conclusion: Central pathology review by expert gynaeco-pathologists changed histological type, grade or other items in 43%
of women with HR-EC, leading to ineligibility for the PORTEC-3 trial in 8%. Upfront pathology review is essential to ensure
enrolment of the target trial-population, and to avoid over- or undertreatment, especially when treatment modalities with
substantial toxicity are involved.
This study is registered with ISRCTN (ISRCTN14387080, www.controlled-trials.com) and with ClinicalTrials.gov (NCT00411138).
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Introduction
Adjuvant treatment of women with endometrial cancer (EC) is
based on clinicopathological risk factors, such as histological
grade, myometrial invasion, age and lymph-vascular space inva-
sion (LVSI) [1–3]. A minority of patients (15%) have high-risk
disease features, which include endometrioid endometrial carci-
noma (EEC) of FIGO stage I grade 3 with deep invasion or with
substantial LVSI; stage II or III EEC; or non-endometrioid histol-
ogies (NEEC) stage I–III [1–4]. For these patients higher risks of
distant metastases and EC-related death have been reported, and
adjuvant chemotherapy may be considered [5–8].
As these high-risk criteria comprise different features of the
pathology diagnosis, reproducibility is essential. Studies of path-
ology review by expert subspecialty pathologists, however, have
shown that evaluation of female reproductive tract pathology had
the highest rates of discrepancies between original and review
pathology assessment including discrepancies with consequences
for treatment [9]. Challenges for pre-treatment pathology review
are that review is time-consuming and expensive, that timelines
are tight and logistical procedures are complicated.
The PORTEC-3 trial is an international randomised phase III
trial of adjuvant therapy in high-risk EC (HR-EC). Women with
HR-EC were randomly allocated (1 : 1) to pelvic radiotherapy
(RT) alone or RT plus concurrent and adjuvant chemotherapy.
Primary end points are overall survival and failure-free survival.
To select patients with true HR-EC and avoid unnecessary inten-
sive treatment in lower-risk cases, upfront pathology review was
carried out by expert gynaeco-pathologists of the participating
groups to confirm HR-EC and eligibility for the study.
The current analysis was done to establish the value of upfront
pathology review. The aims were to explore the proportion of
patients who were ineligible for the PORTEC-3 trial after pathol-
ogy review, and to evaluate inter-observer variability between
original and review pathology assessments.
Methods
Study design and participants
PORTEC-3 is a randomised Intergroup trial led by the Dutch
Gynaecological Oncology Group, with participating groups MRC-NCRI
(UK), ANZGOG (Australia and New Zealand), MaNGO (Italy), Fedegyn
(France) and CCTG (Canada). Surgery comprised hysterectomy with
salpingo-oophorectomy. Lymphadenectomy was at the discretion of the
participating centres. For serous or clear cell cancers, surgical staging
including omentectomy; peritoneal biopsies and lymphadenectomy was
recommended.
Details on patient selection and treatment have been described in a
previous publication [10]. Eligible patients had EEC of FIGO 2009 stage
1A grade 3 with LVSI; IB grade 3; stage II, IIIA, IIIBparametrial or IIIC; or
NEEC stage IA–III.
Patients were randomised (1 : 1) to RT (48.6 Gy) or RT plus adjuvant
chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT,
followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2
every 3 weeks).
Written informed consent (IC) was obtained from all patients. The
protocol was approved by the Dutch Cancer Society and the Ethics com-
mittees. Participating groups obtained their own IRB and ethics appro-
vals and were funded by separate grants.
Procedures
Each participating group had appointed expert gynaeco-pathologists as
reviewers for the study. After surgery, the pathology diagnosis was made
by the regional pathologist. In case of HR-EC, all histopathology slides
and a copy of the pathology report were sent for pathology review as part
of patient management, to confirm HR-EC within 1 week, with the aim
to ensure that only true HR-EC cases were informed and enrolled in the
trial. If IC was given, pathology review for the PORTEC-3 trial was com-
pleted with trial-specific items. Upon consent for storage of tumour tis-
sue for translational research a formalin-fixed paraffin-embedded
(FFPE)-block was centrally stored. All other blocks and slides were sent
back to the referring centre.
The items for original and review pathology included WHO histologi-
cal type, grade, depth of myometrial invasion, distance to serosa or
serosal breach, LVSI, cervical stromal involvement, involvement of the
tubes and/or ovaries and lymph node involvement. Histological type was
evaluated as endometrioid, serous, clear cell, mixed (endometrioid with
serous/clear cell components), mucinous, or other histologies according
to WHO-classification [11]. Mixed tumours were classified as serous or
clear cell when this component was at least 25%, otherwise as mixed.
Mucinous tumours were grouped with EEC for analysis. Histological
grading was done according to WHO [11]. NEEC was considered high
grade per definition (grade 3). The differences in histological grading
between original and review pathology were evaluated for EEC.
Immunohistochemistry (IHC) was carried out only incidentally, at the
discretion of the review pathologist and only if FFPE-blocks were avail-
able at time of the central review process.
For the current analysis, anonymised original and review pathology
reports from both randomised and non-randomised patients in the
Netherlands (NL) and the UK (UK) were assessed. These two countries
were chosen as they had the largest number of patients in the trial
(together 48%) and all pathology reviews had been done at two centres in
each country. For the UK patients, the review pathologist provided a
short confirmation of HR-EC and eligibility. For the randomised
patients, the review report was completed after IC was given.
Outcomes
Discrepancies between original and central pathology review were
assessed as discrepancies with and without change of eligibility for the
PORTEC-3 trial. Reasons for non-eligibility were checked by two expert
gynaeco-pathologists (TB and NS).
Statistical analysis
The data were collected in a SPSS database (version 23.0). For the com-
parison of the pathology items, Cohen’s kappa value (j) was used [12].
For the interpretation of the j values the scale proposed by Landis and
Koch was used [13].
Differences between eligible women who were included or declined




The PORTEC-3 trial included 686 patients (2006–2013), of
whom 145 were recruited in NL and 184 in the UK. Slides from
1295 patients (395 NL, 900 UK) were sent for pathology review.
Fifteen original pathology reports (9 NL, 6 UK) were not available
for analysis. Fifty-four patients (18 NL, 36 UK) were ineligible
based on the original pathology report, which was confirmed by
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pathology review and they were therefore excluded from the anal-
ysis. A total of 1226 patients (368 NL, 858 UK) were eligible based
on local pathology and were included in this analysis (see Figure
1, Table 1 and supplementary Table S1, available at Annals of
Oncology online).
Discrepancies and inter-observer variability
A total of 6356 pathology items were evaluable for both original
and review pathology. For 679 items (11%) there was a discrep-
ancy between original and review pathology. The highest agree-
ment was found for serosal breach (98%) and cervical stromal
involvement (94%), and most disagreement for histological type
(15%) and grade (20%; see Table 2).
In 532 cases (43%) at least one pathology item changed after
review, which led to ineligibility for the PORTEC-3 trial in 8%
(n¼ 102; Table 3). Most frequent reasons were change of histo-
logical type (34%, n¼ 35), cervical stromal involvement (27%,
n¼ 27) and change of histological grade in 19% (n¼ 19), which
was similar between the NL and UK cohorts. Eighty-three of these
102 became low risk after central pathology review, while in 19
cases the histological type was reclassified as carcinosarcoma;
these were therefore still high risk but were not eligible for the
PORTEC-3 trial.
Highest rates of inter-observer variability were found for histo-
logical type (j¼ 0.72), LVSI (j¼ 0.72) and histological grade
(j¼ 0.70; Table 2). See supplementary Table S2, available at
Annals of Oncology online for results by country and supplemen
tary Figure S1, available at Annals of Oncology online. Lowest
inter-observer variability was found for cervical stromal invasion
(j¼ 0.87), with overall agreement of 94%. However, a discrep-
ancy here led to ineligibility for the trial in 27/69 (39%) of cases.
Serosal breach was present in only 5% of cases. Although agree-
ment was high for both countries (97% and 99%), j values
differed (NL j¼ 0.83 versus UK j¼ 0.63), showing that j values
are less reliable for items with few observations.
Histological type and grade
Figure 2 shows the agreement of histological classification and
grade. Overall agreement of histological type was 85%; discrepan-
cies led to ineligibility in 19% of cases (Table 2). Discrepancies
were found for all histologies, although the agreement was high-
est for EEC.
The overall agreement for histological grade was 80%; 16%
(n¼ 113) were downgraded at review pathology, with most fre-
quent shifts (76 cases) from grade 2 to 1. In 4% (n¼ 26), the
grade was higher at review.
Discussion
In the PORTEC-3 trial of adjuvant RT with or without chemo-
therapy for women with HR-EC, upfront pathology review was
carried out before patient counselling to ensure that only true
HR-EC patients were informed about the trial, and that the trial
only enrolled true HR-EC cases. The expert gynaeco-pathology
review changed the eligibility for 102 women (8%), most fre-
quently due to changes in histological type or cervical stromal
involvement. These lower-risk patients did therefore not risk
receiving more intensive and potentially toxic treatment.
Furthermore, a true HR-EC study population in the PORTEC-3
trial was ensured. For 19 patients the histological type changed to
carcinosarcoma and although they were high risk, they were not
eligible for the trial.
The inter-observer agreement between original and review
pathology was highest for cervical stromal invasion. The most fre-
quent discrepancies were found for histological type, histological
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Figure 1. CONSORT diagram.
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Table 1. Major pathology criteria of the eligible patients (n5 1226)
Major pathologic criteria NL patients (n5368) UK patients (n5 858)
n % n %
Age <60 100 37% 239 28%
60–69 110 41% 373 44%
70 58 22% 243 28%
Missing 100 3
FIGO stage (2009) IA 72 20% 138 16%
IB 93 26% 178 21%
II 99 27% 263 31%
IIIA 43 12% 97 12%
IIIB 18 5% 62 7%
IIIC 40 11% 101 12%
Missing 3 19
Histological type Endometrioid or mucinous 262 71% 501 59%
Serous or mixed serous 66 18% 193 23%
Clear cell or mixed clear cell 31 8% 111 13%
Othera 9 2% 45 5%
Missing 0 8
Histological grade 1 81 22% 155 18%
2 53 14% 135 16%
3 127 35% 201 24%
NEEC 107 29% 354 42%
Missing 0 13
Myometrial invasion <50% 135 37% 215 38%
50% 233 63% 346 62%
Missing 0 297
Growth through serosa Yes 21 6% 31 4%
No 346 94% 675 96%
Missing 1 152
Cervical glandular involvement Yes 135 38% 172 43%
No 224 62% 230 57%
Missing 9 456
Cervical stromal involvement Yes 138 38% 339 47%
No 225 62% 382 53%
Missing 5 137
LVSI Yes 198 54% 287 60%
No 169 46% 194 40%
Missing 1 377
Involvement of the ovaries Yes 46 13% 67 9%
No 322 87% 666 91%
Missing 0 125
Lymph node involvement Not applicable 252 69% 553 66%
No malignancy 73 20% 184 22%
Metastasis 41 11% 101 12%
Missing 2 20
Parametrial involvement Yes 24 13% 61 16%
No 167 87% 326 84%
Missing 177 471
Missing values were not taken into account to the percentages.
The pathology criteria of the NL versus the UK patients were based on review pathology.
aOther histology includes undifferentiated, carcinosarcoma or mixed combinations other than serous/clear cell with endometrioid.
FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymph-vascular space invasion; EEC, endometrioid endometrial cancer; NEEC, non-
endometrioid endometrial cancer.
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grade and presence of LVSI. While many of these discrepancies
did not affect eligibility for the current study, they were impor-
tant for prognosis and adjuvant treatment of patients in clinical
practice.
Discrepancies in gynaeco-pathology diagnosis between origi-
nal and review pathology have been reported before. A Canadian
study reported EC as the tumour site with most frequent differen-
ces in pathological assessment [14]. Another Canadian cohort
reported major discrepancies in 8% of biopsies and hysterectomy
specimens taken together, and in 12% of hysterectomy speci-
mens. The most frequent diagnostic discrepancies were assess-
ment of myometrial invasion and histological subtype [15].
In the PORTEC-1 and -2 trials pathology review showed that
24% and 14%, respectively, of patients were in retrospect ineligible,
while this was 8% for the PORTEC-3 trial [1, 16, 17]. Eligibility in
the PORTEC-1 and -2 studies was determined by grade, myome-
trial invasion and histological type. Differences in eligibility were
often caused by shift of grade 2 to grade 1, while such grade shift
did not affect the PORTEC-3 trial where patients had to have either
grade 3 or NEEC or advanced stages. Minor discrepancies in grade
or histology changed the eligibility for the PORTEC-3 trial in only
a minority of patients. However, some shift of grade 2 to grade 1
was seen in the PORTEC-3 trial as well. Previous studies have
shown that the intermediate grade is the least reproducible and
Table 3. Reasons for ineligibility of 102 patients based on pathological review report
Pathology variables Cohort (n5 102) NL cohort (n5 42) UK cohort (n560)
n % n % n %
Histological type 35 34 14 33 21 35
Histologic gradea 19 19 7 17 12 20
Myometrial invasion 7 7 3 7 4 7
Cervical involvement 27 27 12 29 15 25
LVSI 4 4 2 5 2 3
Otherb 10 10 4 10 6 10
Total ineligible patients 102 100 42 100 60 100
Percentage of total cohort 102 8 42 11 60 7
aGrade shift for endometrioid endometrial carcinoma.
bOther reasons included the absence of involvement of the ovaries, tube or parametrium, or other primary tumour site (cervix, tube or adnex).
LVSI, lymph vascular space invasion; NL, Netherlands; UK, United Kingdom.
Table 2. Inter-observer variability between original and review pathology report for the total cohort
Total cohort





















Histological type 1217 9 185 15% 35 19% 150 81% 0.72
Histological grade
(EEC only)
701 0 139 20% 19 14% 120 86% 0.70
Myometrial invasion 923 304 88 10% 7 8% 81 92% 0.79
Cervical glandular
involvement
626 600 73 12% 0 0% 73 100% 0.73
Cervical stromal
involvement
1063 163 69 6% 27 39% 42 61% 0.87
LVSI 762 464 101 13% 4 4% 97 96% 0.72
Growth through
serosa
1064 162 24 2% 0 0% 24 100% 0.76
Total 6356 1702 679 11% 92 14% 587 86% NA
aTotal number of pathology items available for comparison between original and review pathology.
bTotal discrepancies/total number of pathology items available for analysis.
cNumber of pathology items leading to ineligibility/total discrepancies.
dNumber of pathology items not leading to ineligibility/total discrepancies.
LVSI, lymph vascular space invasion; EEC, endometrioid endometrial cancer.
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that a two-tiered grading system assessing high versus low grade
would be preferable [18–20]. The lower inter-observer variation in
the current study could also reflect the increasing standardisation
of pathology criteria and subspecialty training.
Frequent causes of discrepancies were assessment of histologi-
cal type and cervical involvement. Several studies have addressed
challenges in diagnosing serous, clear cell and mixed cancers, the
level of agreement varying from 62% to 83% [21–23]. In the
study by Han et al. [21], there was consensus on histological type
in 72% of cases. With a panel of three IHC markers the agreement
increased to 96% [21]. The use of IHC was not routine practice in
the period of the PORTEC-3 trial and was only carried out in
incidental cases.
Variations in defining cervical stromal involvement have also
been reported in a study of 76 cases reviewed by 6 expert gynaeco-
pathologists with agreement in only 50%. Difficulties comprised
the definition of the junction between the lower uterine segment
and the endocervix, and the distinction between unattached
tumour components or true cervical stromal involvement [24].
A limitation of this study could be that the pathology reviews
took place at four university centres, and inter-observer varia-
tions between these gynaeco-pathologists were not assessed. The
percentages of major discrepancies were, however, quite similar
between the two countries. In the PORTEC-2 trial, higher risk of
distant metastasis and lower survival were found for patients who
were considered ‘high-risk’ after central review pathology, sug-
gesting that the review pathology was more reliable to predict
prognosis when compared with the original pathology [16].
Creating a well-defined trial population with confirmed eligi-
bility by upfront pathology review should be considered the
standard for future scientific studies. Expert consultation is being
increasingly used, but pathology review might not be part of the
standard procedure, because it is time consuming and expensive.
To this purpose, further standardisation of pathology criteria,
expert education and subspecialisation in gynaeco-pathology are
essential, as well as rapid access to expert consultation. The tran-
sition to digital pathology will greatly facilitate rapid consulta-
tion. Introduction of IHC and molecular analysis using the
TCGA molecular subgroup classification will further improve
risk assignment [25, 26].
A substantial proportion of eligible women declined participa-
tion in the trial, mostly because they did not want to receive che-
motherapy. Younger patients and those with a more advanced
stage of disease more often consented to participate in the trial
(supplementary Table S1, available at Annals of Oncology online).
The potential treatment consequences for patients should be the
main reason to incorporate pathology review in daily practice. In
the current study, most patients with discrepancies were down-
graded and were spared unnecessary treatment.
In conclusion, upfront pathology review by expert gynaeco-
pathologists identified changes in histological type, grade or
other items in 43% of patients. Of these, 8% of patients were
found ineligible for the trial. This resulted in a true HR-EC popu-
lation and reliable pathology assessment in the PORTEC-3 trial,
which ensures the quality of future translational research.
Upfront pathology review is to be preferred in future
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Figure 2. Histological type (A) and histological grade evaluation (B) in original and review pathology.
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gynaecological oncology trials and in daily practice. The transi-
tion to digital pathology will strongly facilitate rapid expert path-
ology consultation.
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